Prompted by legislation, plans head into HSA territory

The biggest advantage of suzetrigine would be that it helps patients avoid the use of opioids for acute pain. The FDA’s goal date for suzetrigine is Jan. 30, 2025.

Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.

CVS Health recently appointed Len Shankman as president of Pharmacy and Consumer Wellness and Lucille Accetta as chief pharmacy officer.

In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.

The out-of-pocket cost for MS disease-modifying therapies jump by 217% going from $750 per year in 2012 to $2,378 per year in 2021.

Psilocybin-assisted therapy, which involves using the active ingredient from "magic mushrooms," could benefit roughly 5 million people currently receiving treatment for major depressive disorder and treatment-resistant depression if the FDA approves it.